Joshua Brody, MD

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai, discusses treatment challenges in DLBCL care.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai, discusses the unmet needs of patients with DLBCL.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai, discusses the challenges of researching combination therapies.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai, discusses the latest advancements in the treatment of DLBCL.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at the Icahn School of Medicine at Mount Sinai, discusses the latest advancements in DLBCL subtying and classification.

In this video, Joshua Brody, MD, discusses the results of the IELSG37 randomized trial, which examined whether radiotherapy is necessary after front-line chemoimmunotherapy for patients with primary mediastinal B-cell lymphoma.

In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.

In this video, Joshua Brody, MD, discusses an update of the ZUMA-7 trial, which was presented at ASCO Annual Meeting.

In this video, Joshua Brody, MD, discussed the results of the SWOG S1826 trial of nivolumab vs. brentuximab vedotin in advanced-stage classic Hodgkin lymphoma, which were presented at ASCO Annual Meeting.